The University Zurich spin-off REMUUN has secured CHF 150,000 from Venture Kick to develop a modular platform designed to accelerate the discovery of precision antibodies. This approach aims to significantly improve immunotherapies used in treating cancer and related diseases.
The global market for monoclonal antibodies is projected to surpass USD 300 billion by 2025. However, current antibody development processes are often slow, expensive, and limited in therapeutic scope, reducing the speed and effectiveness of new treatments, particularly in cancer and immune system diseases. REMUUN, cofounded by Richard Chahwan, supported by Paulina Wyrzykowska and Romina Fetti, is developing a proprietary, patented MEGA platform that replicates the natural antibody diversification process in a laboratory setting.
The platform's modular design allows for rapid and accurate generation of tailored monoclonal antibodies. By building on its expertise in the interactions between immune systems and tumors, REMUUN seeks to deepen scientific understanding and produce more effective immunotherapies.
The biotech startup plans to use the CHF 150,000 provided by Venture Kick to accelerate its growth. The funds will support REMUUN in establishing strategic partnerships with pharmaceutical companies, initiating the development of a new generation of antibody-based therapies, and strengthening its intellectual property portfolio.
"Venture Kick has been an incredible support for REMUUN: The funding, mentorship, and access to a broad network of experts have not only accelerated our research but also sharpened our business strategy,” highlighted Richard Chahwan, Founder and interim CEO of REMUUN. “The process challenged us to think bigger, refine our vision, and position REMUUN as a potential disruptor in antibody development. We’re incredibly grateful for this support and thrilled for the journey ahead!"
(Press release/RAN)
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
Please login or sign up to comment.
Commenting guidelines